surmount-osa trial tirzepatide results VisualAbstract: Improved Outcomes in Patients with Obstructive Sleep Apnea and Obesity Terzapatid in Managing OSA

Interestingly, when comparing the nocturnal plasma levels between individuals with schizophrenia and MDD, it was found that the levels in MDD are lower than those seen in schizophrenia 130

Proc Natl Acad Sci USA 1981;78(6):3483-3486

Generally, the treatment starts with a dose of 25mg daily and then gradually increases weekly by 25 50mg

Time dependence refers to the pattern of side effects being most prominent during treatment initiation and dose increases, then declining as the body adapts

Other possible effects include fatigue, headache, decreased appetite (which is partly intended), and injection site reactions

Among the possible mechanisms underlying DDIs, those related to delayed gastric emptying have been most extensively studied